Kymriah Cost, Effectiveness, How it Works, Treatment Centers. There’s a new way to treat cancer and it has recently gained the approval of the U.S. Food and Drug Administration. Kymriah is a gene-therapy approach to cancer treatment which is pioneered by Swiss drugmaker Novartis. The drug maker is also going through the process of having the treatment approved by the European Medicines Agency and be made available in Europe.
Does it Work? Well, it wouldn’t have gained the approval of the FDA if it does not work, right? However, the Kymriah cell treatment has only been approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. In other words, this is not meant for all cancer patients. As you may note in the Reuters report below, the drug maker is seeking to also get Kymriah approved for adult patients.